PFS and OS according to cohort. PFS (A) and OS (B) in cohort A (ibrutinib plus obinutuzumab), relapse patients. PFS (C) and OS (D) in cohort B (ibrutinib, obinutuzumab, and venetoclax), relapse patients. PFS (E) and OS (F) in cohort C (ibrutinib, obinutuzumab plus venetoclax), untreated patients.